Estimates from the U.S. Surveillance, Epidemiology, and End Results registry suggest that melanoma incidence will reach 70,230 cases in 2011, of whom 8790 will die. The rising incidence and predilection for young individuals makes this tumor a leading source of lost productive years in the society.
M elanoma is a disease of increasing incidence that exacts a disproportionate toll among the young in the population. The Surveillance Epidemiology and End Results statistics suggest that, of the estimated 70,230 with incident melanoma in 2011, 58.5% of patients will be younger than 64 years. 1 Patients with locally advanced disease have a relatively high risk of recurrence and death despite surgery. At present, the only Food and Drug Administration (FDA)Yapproved adjuvant treatment option for patients with high-risk disease (primary tumor thickness of Q4 mm [T4 lesions] and/or regional lymph node metastases) is interferon->-2b (IFN->-2b).
In this article, we delineate the clinical prognostic factors that portend a heightened risk of recurrence and outline the development of IFN-> in the adjuvant setting with a focus on the various clinical trials that led to the adoption of high-dose interferon (HDI) as the standard adjuvant therapy for this disease.
We discuss other evolving options including vaccines, CTLA-4 blockade, chemotherapy, and radiotherapy (RT)Vwhich have yet to demonstrate reproducible survival benefits in randomized phase III trials and hence remain experimental at this time.
With the recent FDA approval of ipilimumab (Yervoy) and vemurafenib (Zelboraf) for the treatment of metastatic melanoma, a once-stagnant field has been rejuvenated. 2Y4 Work is already underway using these agents in the adjuvant setting. This article updates prior adjuvant reviews 5, 6 and meta-analyses. 7Y10
MATERIALS AND METHODS

Search Strategy and Selection Criteria
A systematic search strategy was performed using the MEDLINE, EMBASE, Cancerlit, Cochrane, ISI, and Web of Science databases for articles published between January 1, 2002, and November 1, 2011. MeSH headings used included ''melanoma, advanced,'' and ''melanoma, adjuvant'' or ''melanoma, interferon.''
DISCUSSION
Clinical Prognostic Factors in Malignant Melanoma
Major prognostic features associated with an increased risk of recurrence and mortality in the American Joint Committee on Cancer (AJCC) Melanoma Staging Database have been incorporated into the revised melanoma staging manual of the AJCC and International Union against Cancer. 11 At the level of the primary tumor, 3 factors are critical: primary tumor thickness (Breslow), ulceration, and mitotic rate. Primary tumor thickness remains the single most important factor with 5-and 10-year survival rates declining commensurate with increasing tumor depth: 10-year survival in patients with T1 melanomas (0.00Y1.00 mm thickness) is 92% but only 50% in patients with T4 melanomas (94.00 mm thickness). Primary tumor ulceration was only added to the staging criteria in 2009Von the basis of the observation that survival rates with an ulcerated melanomas are consistently lower than for nonulcerated melanoma of equivalent T category; for each thickness, the outcome for an ulcerated melanoma proved to be similar to that of patients with a nonulcerated melanoma of the next higher thickness (T) category in the 2009 staging manual. Increasing mitotic rate (defined as the number of mitoses per square millimeter) marks a more aggressive lesion and is associated with worse survival at every T category. In fact, registry data suggest that mitotic rate is the second most powerful predictor of survival, with a potential for negatively impacting survival even in otherwise favorable prognosis disease states. Considering nonulcerated T1 melanomas, 10-year survival rates are 95% for lesions with mitotic rate of less than 1/mm 2 and drop to 88% for lesions with mitotic rate of 1/mm 2 or greater. Mitotic rate has also replaced the Clark depth of invasion in defining T1 lesionsVT1a melanoma refers to 1.00-mm-thick nonulcerated lesions or less with mitotic rate of 1/mm 2 or less with T1b lesions referring to 1.00-mm-thick melanomas or less that are either ulcerated or have a mitotic rate greater than 1/mm 2 .
Melanoma has a predilection for lymphatic seeding, and the risk of regional lymph node involvement increases with tumor thicknessV2% to 5% for Breslow depth of 1.00 mm or less but 34% for T4 lesions. 12 Increasing lymph node tumor burden is associated with worse survivalVthe 5-year survival of stage III patients, subdivided by the extent of lymph node involvement, shows a steady decline from 78%, to 59%, and 40% for stages IIIA, IIIB, and IIIC, respectively. In the seventh edition of the AJCC staging system, nodal micrometastases can be defined by immunohistochemical staining rather than by hematoxylin-eosin alone, and the concept of a minimum threshold of lymphatic tumor burden was abolished with any degree of involvement considered significantVwhether micrometastatic or macrometastatic.
When considering systemic metastatic disease, the number of metastatic sites, the sites of distant metastases, and the serum lactate dehydrogenase (LDH) enzyme level are important prognostic factors. LDH expression may be related to the progression of melanomasVbeing barely detectable in nevi but strongly expressed in thick primary melanoma and in metastatic melanoma. 13 The significant drop-off in 1-year survival between patients with M1a and M1b disease (62% and 53%) compared with M1c disease (33%) underscores the importance of detecting nonlung visceral metastases and assaying LDH in prognostication.
Indications for Adjuvant Therapy
By definition, adjuvant therapy is offered after definitive surgical treatment has removed all detectable disease and is given with the intent of reducing relapse risk due to occult disease.
Currently, adjuvant therapy with the FDA-approved regimen of HDI for 1 year or enrollment in a clinical trial should be considered for patients whose estimated risk of recurrence exceeds 30%; that is, patients with node-positive melanoma and T3b or T4 node-negative disease.
Immunotherapy
Cancer immunotherapy has evolved considerably since Coley's observations of tumor shrinkage with inoculation of bacterial products into tumors. For melanoma, the lack of effective chemotherapeutic options and the observations of anti-tumor response rates of 15% to 20% with systemic administration of IFN-> led to the consideration of adjuvant application of this agent. The biology of this agent and the data that led to the FDA approval of IFN-> for adjuvant treatment of stage IIB-III resectable melanoma in 1995 follows.
Immunotherapy: IFNVMechanism of Action
Based on functional and structural differences, IFNs are subclassified into types 1 and 2. Type 2 IFN (IFN-F) is produced by T H 1 cells and exerts a weak antiviral and anti-tumor effect and upregulates T H 2 activity. Type 1 IFNs (IFN->, IFN-A, and IFN-U) are produced primarily by dendritic cells in response to infectious agents. Signaling via the IFN-> receptor, type 1 IFNs connect the adaptive and innate arms of the immune response and have potent apoptotic, antiproliferative, antiangiogenic, and immunoregulatory properties.
IFN->'s mechanism of action in melanoma is thought to be immunomodulatory rather than directly cytotoxic or antiangiogenic. Accumulated evidence suggests that anti-tumor immunity is abrogated by the tumor through immunosuppressive circuits including the cascade triggered by constitutive activation of STAT3 in the tumor 14 with the elaboration of vascular endothelial growth factor, interleukin 10 (IL-10), and tumor growth factor A, as well as regulatory T (Treg) cells within the tumor microenvironment. 15 In addition, it is known that type 1 IFNs play a critical role in T-cell priming, especially that mediated by dendritic cells, an effect that is subsequently diminished as tumor outgrowth occurs and may be reversed by IFN adminis-trationVsupported by observations from Gajewski et al 16 who have reported that the in vivo expression of IFN-> or IFN-A by retroviral transduction can lead to total rejection of melanoma in a murine model. Observational data from a clinical trial involving patients with stage IIIB/C melanoma given neoadjuvant HDI before definitive lymph node dissection suggested that IFN-> caused an influx of T cells and dendritic cells to a degree that correlated directly with responses. 17
Immunotherapy: IFNVClinical Development
After initial evidence of activity of IFN-> in metastatic melanoma, multiple phase II trials were conducted, and response rates observed were similar to single-agent chemotherapy (È13%Y24%). Notably, durable responses that lasted years led to investigations in the adjuvant setting for high-risk resected melanoma. The studies that followed have differed primarily in relation to dosage of IFN-> (low dose, e3 MU/dose; intermediate dose, 5Y10 MU/dose; and high dose, Q10 MU/dose) as well as the subspecies of IFN-> used (IFN->-2a, IFN->-2b, and IFN->-2c) and the schedule used for therapy; these are summarized in Table 1 .
The initial U.S. Cooperative Group trials primarily involved HDI, and of these, 2 in particular had significant therapeutic results in relation to reduction in recurrence and/or mortality. The North Central Cancer Treatment Group (NCCTG) trial tested a regimen of 20-MU/m 2 dose of IFN->-2a administered intramuscularly thrice weekly for 12 weeks for stage II and III disease, whereas the Eastern Cooperative Group (ECOG) trial (E1684) tested aninduction phase of 1 month of daily intravenous IFN->-2b at 20 MU/m 2 , followed by 11 months of maintenance therapy at 10-MU/m 2 dosage subcutaneously (SC) 3 d/wk. 18, 19 The NCCTG trial demonstrated improvements in median disease-free survival (DFS) and overall survival (OS) that were nonsignificant, with higher-risk patients appearing to benefit disproportionately. E1684 was a landmark studyVdemonstrating statistically significant improvements in both DFS and OS among patients with high-risk disease (T4 primaries or regional lymph node metastases) in a randomized controlled setting that paved the way for FDA approval of HDI in high-risk T4 (stage IIB) and N1Y2 (IIIA/B) patients as defined by this trial.
Balanced against these benefits, the toxicity observed with 67% incidence of grade 3 toxicity, 9% incidence of grade 4 toxicity, and 2 early treatment-related hepatotoxic deaths in E1684 raised concerns over the tolerability and compliance with this regimen and prompted investigators to study lower doses of IFN->. A variety of alternative regimens using lower doses of IFN-> were then tested including the very low dose regimen (1 MU SC every other day) tested in EORTC 18871 30 (stage IIB/III) and the lowdose regimen (3 MU SC thrice weekly) tested in WHO Melanoma Program Trial 16 28 (stage III), Scottish Melanoma Cooperative Group trial 29 (stage IIB/III), UKCCCR AIM-High trial 31 (stage IIB/III), E1690 20 (T4, N1), and the 2010 German DeCOG study 32 (T3Nx in the context of the 2012 DeCOG study)Vwithout any OS benefit being observed. The 2008 German DeCOG study 33 demonstrated a survival benefit for LDI but was powered primarily to assess the benefit of combination LDI with dacarbazine and not designed to evaluate the low-dose regimen per se.
Two trials of the low-dose regimen by Austrian (AMCG trial 26 ) and French (FCGM trial 27 ) groups were carried out in patients with stage II disease (T2Y4 N0 M0)Valthough the Austrian trial reported improvements in DFS but not OS, the French trial reported 19 ‡Kirkwood et al. 20 §Kirkwood et al. 21 ||Kirkwood et al. 22 ¶Chiarion-Sileni et al. 23 #Eggermont et al. 24 **Bouwhuis et al. 25 † †Pehamberger et al. 26 ‡ ‡Grob et al. 27 § §Cascinelli et al. 28 ||||Cameron et al. 29 ¶ ¶Kleeberg et al. 30 ##Hancock et al. 31 ***Hauschild et al. 32 † † †Garbe et al. 33 NS indicates not significant; S, significant. 24 (stage IIB/III) demonstrated a 7.2% increase in distant metastases-free survival (DMFS), but this was not statistically significant and no OS benefit was observed.
An interesting alternative approach to adjuvant therapy was taken by the Italian Melanoma Intergroup in a randomized phase III study that enrolled 336 patients with stage III disease to received either standard HDI or intensified HDI (IHDIVIFN->-2b 20 MU/m 2 intravenously 5 d/wk for 4 weeks every other month for 4 cycles). 23 At the 5-year mark, there were no statistically significant differences in either relapse-free survival (RFS) or overall survival (OS) and similar toxicity rates among patients in both groups. Although mature survival data have yet to emerge from evaluation of intensive IHDI, this regimen may be more tolerable than conventional HDI.
Survival analysis in E1684 suggested that the greatest reduction in relapse occurred relatively early arguing for the importance of the regimen's induction phaseVand was sustained thereafter to more than a decade. The benefit of an abbreviated course of 1 month of therapy has been prospectively tested in the Hellenic study (induction HDI only vs induction and maintenance) and in E1697 (4 weeks of HDI vs observation). 34, 35 The Hellenic trial tested noninferiority of an induction-only arm and suggested little difference between this and the longer 1-year treatment with the modified dosage of IFN tested, on the basis that the 3-year relapse rate in the induction-only arm was less than 15% higher than the relapse rate of the 1-year group. However, the relatively small size, use of a reduced dose IFN-> regimen, and the lack of an observation arm make these results hard to interpret. At the interim analysis of E1697 after 1150 of a planned 1420 patients were randomized, the study was closed for futility. Taking these results together, it is unlikely that durable benefits are associated with 1 month of intravenous induction therapy alone, and therapy with the full year as in E1684 is now recommended.
Given the accumulated evidence for adjuvant HDI, there is abundant evidence that HDI results in an approximate 30% reduction in RFS with a reduction in mortality that is smaller in 2 studies (E1684 and E1694). Retrospective data from metaanalyses, 8 systematic reviews, 7,10 and a pooled data analysis 36 consistently support the conclusion that HDI increases DFS with a smaller benefit on OS.
Immunotherapy: IFNVPegylated IFN
Pegylated IFN-> was first used in the treatment of hepatitis B/C and pharmacokinetic data from hepatitis studies and phase I/II trials in oncology supported the ability to maintain therapeutic dose levels with once-weekly subcutaneous injections. 37 Trials conducted by the EORTC have demonstrated RFS benefits in the adjuvant setting that has led to the regulatory approval of this agent for adjuvant treatment of stage III melanoma in the United States.
EORTC 18991 investigated the use of pegylated IFN->-2b in patients with resected AJCC stage III melanoma in a randomized phase III trial. 38 Therapy comprising ''induction'' doses that are somewhat higher (Peg-IFN->-2b SC 6 Kg/kg a week for 8 weeks) followed by maintenance doses (weekly SC injections at 3 Kg/kg for 5 years) was compared with observation. Recently presented 7.6-year follow-up data showed an improved RFS in the treatment arm with no difference in OS or DMFS. Subgroup analysis has revealed that patients with microscopic nodal metastases and ulcerated primaries seemed to benefit disproportionately in terms of RFS/OS and DMFS. This subset analysis finding was buttressed by pooled analysis of EORTC 18952/18991 that spurred interest in investigating adjuvant therapy with Peg IFN> in this subgroup of patients. 39 EORTC 18081 is a prospective trial that will randomize patients with ulcerated primaries to either pegylated IFN->-2b versus observation. For the present, the use of pegylated IFN->-2b in microscopic nodal disease (AJCC IIIA) may be considered as an alternative to HDI for patients unwilling to consider HDI.
Low-dose pegylated IFN->-2b was compared with LDI in a prospective phase III European Association of Dermato-Oncology (EADO trial) that enrolled patients with resected stage IIA-IIIB melanoma (T Q 1.5 mm, without clinically detectable nodal disease). Patients were randomized to either LDI (3 MU SC thrice weekly) for 18 months or low-dose pegylated IFN->-2b (100 Kg of SC once weekly) for 36 months. No differences between groups in terms of RFS, OS, or DMFS were found, although results were likely affected by the 72% dropout rate secondary to serious adverse events in the pegylated IFN->-2b arm (44.6% vs 26.6%). 40
Immunotherapy: IFNVThe Future
The accumulated evidence suggests that adjuvant IFN->-2b therapy has a remarkably sustained impact on RFS with a lesser impact on OS, the basis of which has never been adequately examined in terms of the actual basis of late mortality beyond 10 years. Various groups have attempted to identify prognostic markers of interferon benefit to focus this therapy on patients most likely to benefit.
Recent European data suggest that patients with certain clinical features (ulcerated node-positive disease) benefit disproportionately from IFN->-2b therapy, although multiple prior ECOG and US Intergroup trials have not similarly identified ulceration as a predictor of benefit for higher dosages of IFN. This is planned for prospective evaluation in EORTC 18081, and results of EORTC 18081 are awaited to address this question.
Because the most mature data for high-dose IFN do not suggest any difference in relapse risk reduction among patients with AJCC stage IIB, IIIA, and IIIB resectable disease, it has been reasonable to impute benefit for high-dose IFN in stage IV patients from these results. Thus, if the risk reduction for a patient with stage IIIA disease and stage IIIB disease is È33%, the benefit of this therapy for resectable stage IV may be similar. Conversely, the benefit of adjuvant therapy may diminish with more advanced disease, as has been reported with intermediatedosage regimens of IFN->-2b and Peg IFN. The EORTC 18952 intermediate-dose IFN->-2b trial and EORTC 18991 Peg-IFN trial demonstrated activity chiefly in stage IIIA (N1) patients, and negligible benefits among stage IIIB (N2) patients with notable differences in the patterns of improvement observed. 24, 41 Although both trials recruited high-risk patients, the Nordic IFN trial enrolled more node-positive patients (79%Y81%) compared with EORTC 18952 (74%Y75%). EORTC 18952 demonstrated that the benefits of PEG-IFN were greater in stage IIB/C patients compared with node-positive patients implying that low preoperative tumor burden was predictive of IFN response. However, the Nordic IFN trial suggested that patients with node-positive disease benefited more than node-negative patients, especially when treated with a longer duration of therapy. Assuming that IFN does not exert differential effects across stages, one would assume that any benefit would be more obvious in higher-risk patients who have a higher rate of adverse events and a worse prognosis.
There has been a paucity of trials that have addressed the specific issue of adjuvant therapy in the highest risk cate-goryVresected stage IIIB-C/IV disease. The failed phase III study of Canvaxin in resected stage IV melanoma patients 42 suggests that Canvaxin had no benefit as adjuvant therapy for either resectable stage III or stage IV disease. The role of adjuvant immunotherapy with high-dose IFN has been evaluated in the highest risk category of resected stage IIIB and IV melanoma in 1 phase II trial E2696 (adjuvant HDI combined with GM2 vaccination compared with GM2 alone. 22 However, the phase III E4697 (granulocyte macrophage colony stimulating factor [GM-CSF] vs placebo) and a retrospective case-control study from Mayo that studied the use of adjuvant GM-CSF therapy after surgical resection have suggested that there may be an opportunity to benefit patients with resectable stage IV disease with the use of GM-CSF adjuvant immunotherapy. 43, 44 Specifically in E4697, although the study overall indicated no benefit for GM-CSF over placebo, when stratified by stage, the investigators observed that patients with stage IV M1a/b disease had a significant trend toward improvement in both DFS and OS, whereas stage III patients had no apparent difference. The hazard ratio (HR) for RFS benefit of GM-CSF over placebo in stage IV resected patients was 0.74, whereas it was 0.92 for stage III and HR for survival benefit in stage IV patients was 0.72 and that for stage III was 0.97. This result in patients with stage IV and the highest level of risk should be evaluated further in the future. E1609, which is selectively accruing high-risk patients with resected stage IIIB/IV disease and is prospectively randomizing them to adjuvant therapy with either ipilimumab or HDI, will hopefully provide some clarification in this area.
Autoimmune manifestations after interferon therapy have been associated with improved prognosis in both the E2696 and E1694 U.S. intergroup trials. 45, 46 These were prospectively validated by the results of Gogas et al, 47 where the authors showed that patients receiving IFN-> for either the full year or an abbreviated schedule of 1 month were more likely to develop autoimmune clinical manifestations or autoantibodies and that patients who developed autoimmune manifestations had improved DFS, OS, and reduced rates of relapse and mortality compared with those who did not do so. Other studies using different methods have shown conflicting results and current studies aim to define the immunogenetic basis of autoimmune events. 25 Multiple other candidate biomarkers of interferon response have been studied, including methylthioadenosine phosphorylase expression, YKL-40, S100B, melanoma-inhibiting activity, and tumor-associated antigen 90 immune complex (TA90IC). Notably prospective data for these biomarkers are lacking, and prospective validation would be important to obtain. This is reviewed elsewhere in detail. 48 Approximately 40% to 60% of advanced melanomas possess activating mutations in BRAF, and BRAF inhibitors induce dramatic anti-tumor responses in these patients. Recently presented data suggest that BRAF mutations contribute to immune escape and that BRAF inhibition increases expression of melanocyte differentiation antigens (MDA) and improved recognition by antigen-specific T cells. 49 Given the known effects of interferon on T-cell function, combining interferon with BRAF inhibition may be synergistic on multiple grounds. Other interferon combinations under investigation include HDI and KW2871, a monoclonal antibody targeting GD3 that is a ganglioside expressed on the surface in more than 95% of melanomas. A phase II trial of the latter combination is presently in active accrual (NCT00679289). Although such trials initially only involve patients with metastatic disease, should efficacy be established, it is not unreasonable to consider extending this to the adjuvant setting.
Immunotherapy: Vaccine Therapy
The goal of vaccine therapy is to elicit durable anti-tumor effects that result in sustained clinical responses in a significant proportion of patients treatedVan approach first pursued in melanoma by Morton in 1967. Melanoma vaccines are divided based on the type of the antigen(s) incorporatedVpeptide, ganglioside, and whole cell/ cell lysate. Peptide vaccines have used melanocyte lineage antigens (such as MART-1/Melan-A, gp100, and tyrosinase) that are recognized by cytotoxic T lymphocytes in conjunction with HLA-A2.1 and elicit a direct cytotoxic T-cell response.
Vaccines based on peptide antigens have been studied in large multicenter ECOG trials that have generally recruited pretreated patients with advanced metastatic melanoma. Although only a few patients demonstrated immune responses to any of the peptides, those who did so tended to develop increased T-cell production of IFN-F and had survival times that were far greater than that of patients who did not develop immunity to peptide epitopes.
Of the 7 large randomized trials of adjuvant allogeneic melanoma cell-based vaccines that have been conducted to date, most have been disappointingly negative. In the United States, the trial of the Melacine vaccine in stage II patients and the 2 trials of the Canvaxin vaccine in stage III and resected stage IV patients were negative and the latter showed a trend toward adverse impact. In Europe, the EORTC initially published data suggesting prolonged DFS in patients treated postoperatively with GM2/ Bacillus Calmette-Guérin (BCG) vaccination. 50 However, when investigated prospectively in EORTC 18961, a trend toward adverse DMFS and OS outcomes led to trial termination at second interim analysis for safety concerns. 51 More mature data have suggested no significant difference in any outcome in this trial. An Australian study did demonstrate a nonsignificant increase in OS and RFS among patients treated with a vaccinia melanoma cell lysate vaccine after definitive surgery, although this has not been reproduced by others. 52 The MAGE-A3 antigen is expressed in a wide variety of malignancies including melanoma but is not detected in most normal tissues except for testis and placenta. 53 Unlike peptides that demonstrate major histocompatibility complexYrestricted activity, MAGE-A3 protein vaccination is suitable for a majority (70%) of melanoma patients whose tumors express this antigen and elicits a broad range of nonYmajor histocompatibility complexYrestricted T-cell responses. After a phase I/II study that demonstrated MAGE-3Yspecific antibody and T-cell responses after vaccination in patients with MAGE-3Ypositive tumors, 54 a randomized phase III study known as DERMA has completed enrollment of patients with stage III nodal metastases and detectable MAGE-3 expression in the resected lymph nodes. Results from this trial are pending.
Morton and colleagues developed a polyvalent cultured melanoma cell vaccine (Canvaxin) that was evaluated in stage III melanoma patients after complete resection in a retrospective study that suggested an improvement in median and 5-year specific OS for vaccinated patients. 55 However, when Canvaxin was compared with BCG alone in a phase III randomized controlled trial for patients with resected stage III/IV melanoma, Canvaxin vaccination failed to improve DFS and OS. In fact, the survival for vaccinated patients was diminished, possibly secondary to vaccine-induced immunosuppression that led to early closure of the trial by the data and safety monitoring board for futility. 56 subsequent phase II trials focused on melanoma after promising results in phase I studies. In the phase II trial of patients with advanced relapsed or refractory melanoma who received tremelimumab dosed at 15 mg/kg (intravenously every 90 days), a 6.6% objective response rate (ORR) was observed, all of which were durable and lasted more than 6 months. 57 However, the initial optimism generated by the phase II results were followed by negative results in the registration phase III trial against chemotherapy (temozolamide or dacarbazine) in which tremelimumab did not confer a significant survival advantage at interim analysis (OS tremelimumab 11.76 months vs chemotherapy 10.71 months) and led to early closure. 58 It is also possible that the results of this trial were affected by the open label nature of the study, and its restriction of enrollment to patients with LDH levels less than twice the upper limit of normal. Crossover of patients who were assigned to chemotherapy but then pursued antiYCTLA-4 therapy in expanded-access ipilimumab trials may also have reduced the apparent treatment benefit and diluted the OS statistic. Ipilimumab (Medarex Inc/Bristol-Myers Squibb) is a fully humanized immunoglobulin G1 J monoclonal antibody that blocks CTLA-4. Two recently published phase III studies evaluated the use of ipilimumab in patients with metastatic melanoma in different settings (first and second line) against different comparators (gp100 vaccine and dacarbazine) and arrived at similar conclusions. These data are tabulated in Table 2 .
The earlier phase III MDX010-20 trial compared ipilimumab alone (at a dose of 3 mg/kg), ipilimumab plus a peptide vaccine, and vaccine plus placebo; this trial demonstrated a significant increase in survival rates at both 12 (46% vs 25%) and 24 months (24% vs 14%) compared with the vaccine comparator. 2 The dose of 3 mg/kg was based on results of the randomized phase II dose-ranging study that demonstrated tolerability of the 10-mg/kg dose level. 60 More recently, the results of the second randomized phase III CA184-024 trial that compared ipilimumab (at a dose of 10 mg/kg) plus dacarbazine (850 mg/m 2 ) to dacarbazine with placebo were released at ASCO 2011. 62 This trial enrolled chemotherapynaive patients and a similar schedule MDX010-20 involving 4 induction doses followed by monthly maintenance forresponders was used. The ipilimumab/dacarbazine combination was associated with a survival advantage that was sustained at 3 years. 3 With the success of ipilimumab in the metastatic setting, trials investigating the potential for ipilimumab in the adjuvant setting have been undertaken. These include the ECOG sponsored intergroup trial E1609 based in the United States and EORTC 18071 conducted in Europe comparing ipilimumab against the reference HDI in the United States and against placebo in Europe. Accrual for EORTC 18071 is complete and results are pending, whereas for E1609 accrual is now active, but the trial results are not anticipated until 2014 or after.
Given the high cost and toxicity of these therapies, clinically relevant biomarkers or predictors of response would be invaluable to guide therapeutic decision making. Unpublished MDX010-20 study data suggest that absolute lymphocyte counts (ALCs) seem to increase in a dose-dependent fashion with ipilimumab therapy with high baseline ALCs being associated with improved outcomes. Hamid et al 64 have reported that elevated tumor-infiltrating lymphocyte (TIL), Treg, and indoleamine 2,3-dioxygenase (IDO) levels in pretreatment biopsy specimens are correlated with improved outcomes in patients with metastatic disease receiving ipilimumab therapy.
Immunotherapy: Other Emerging Checkpoints
Other potential immunomodulatory targets include anti-PD-1, anti-OX44, and antiY4-1BB antibodies. Along with CTLA-4, the programmed death 1 (PD-1) receptor is a negative costimulatory circuit that down-regulates T-cell activation and response. PD-1 ligand (PD-L1) is expressed on the surface of melanoma cells, B-cells, dendritic cells, and macrophages, and PD-L1 up-regulation seems to depend on toll-like receptor 4 (TLR-4)Ybased signaling as well as being induced by IFN->. Increased PD-1 interaction has been implicated in maintaining immune tolerance through diminished T-cell effector function and PD-1 blockade has been shown to promote the generation of melanoma antigen-specific cytotoxic T cells (CTLs) and overcome Treg-mediated suppression. 65 OX44 and CD137 are T-cell targets that up-regulate the immune response. Agonistic antibodies anti-OX44 and anti-4-1BB may increase the T-cell response against melanoma.
Thus far, the use of these agents has been limited to early phase trials in metastatic disease and formal results of phase III trials are awaited before the extension of these agents into the adjuvant setting.
Chemotherapy
Several trials have assessed the use of adjuvant chemotherapy after surgical resection in high-risk patients. Multiple small nonrandomized single-center studies have assessed various options including megestrol acetate, vitamin A, vindesine, and dacarbazineVboth singly, and in combination with BCG. However, despite suggestions of benefit, none have been demonstrated in subsequent randomized controlled trial. These data are summarized in Table 3 and are reviewed in detail elsewhere. 70 Two trials of chemotherapeutic combinations have demonstrated increased RFS (but not OS), although no benefit was observed with the combination of dacarbazine/BCG in E1673. 71 66 †Lejeune et al. 67 ‡Fisher et al. 68 §Koops et al. 69 BS indicates barely significant; NS, not significant. The 2008 phase III DeCOG study compared a combination LDI and dacarbazine to adjuvant LDI alone after completion of lymph node dissection. 33 Although the LDI-only arm demonstrated a survival benefit, this trial was not powered adequately to assess the benefit of low-dose IFN over observation.
Although the combination of biologics with chemotherapy (biochemotherapy) has been associated with improvements in response rate and PFS in the metastatic setting, no OS benefit has been observed compared with dacarbazine monotherapy. S0008 is an intergroup phase III study organized by the Southwest Oncology Group (SWOG) testing the benefit of biochemotherapy versus HDI. The study enrolled resectable stage IIIB and IV patients and randomized subjects to either 1 year of HDI or 3 cycles of cisplatin, vinblastine, dacarbazine, IL-2, and interferon given monthly. As both the IL-2 and interferon were dosed substantially below their individual maximally tolerated doses, this trial is really an evaluation of the effect of chemotherapy modulated by IFN/IL-2Valthough completed, trial results are still pending and expected in 2012.
Radiotherapy
In melanoma, RT is rarely indicated in the primary setting as surgical excision with wide margins provides valuable diagnostic and prognostic information. However, the risk of local relapse despite CLND is 15% to 20% and elevated to 30% to 50% for patients with extracapsular lymph node extension, involvement of 4 or more nodes, or bulky disease (exceeding 3 cm in size), cervical lymph node location, and recurrent disease. In such patients, adjuvant RT may be valuable especially if patients are intolerant of HDI therapy.
Multiple nonrandomized trials have evaluated the use of RT in this setting and have generally concluded that adjuvant RTwas associated with improved local and regional control rates without any survival benefit. Similar to the data from breast and prostate cancer, hypofractionation seems to be equally efficacious as standard dosing in treating melanoma. 72 ANZMTG 01.02/TROG 02.01 is a more recent prospective multicenter phase III trial involving clinical sites in Australia, New Zealand, and the Netherlands. 73 A total of 217 patients from 16 centers were randomized to observation versus regional nodal basin RT (48 Gy in 20 fractions). Although RT use resulted in a statistically significant improvement in regional control (HR, 1.77; 95% confidence interval, 1.02Y3.08; P = 0.041), it had no impact on survival. In fact, RT use was actually associated with poorer survival (31 months versus 47 months, P = 0.14). There are no insights to this paradoxical observation at this time. Several follow-up studies including RTOG 9302 (phase III study of postoperative adjuvant RT in patients with cutaneous melanomas of head and neck) were planned but have since been stopped secondary to nonaccrual. There remains a paucity of prospective data evaluating the use of RT especially in patients with advanced regional nodal disease and extracapsular disease extension in whom the role of HDI in preventing systemic or locoregional recurrence is not well defined.
FUTURE QUESTIONS/CONCLUSIONS
Results of multiple U.S. and European intergroup studies (E1684, E1690, E1694, EORTC 18952, and EORTC 18991) have shown that adjuvant IFN-> improves RFS, although the impact on survival seems to be less overall, and for HDI where 2 trials show an impact on OS, the benefit diminishes after 10 years. For pegylated IFN->, the impact has been solely on RFS. Identifying factors that may predict responsiveness of patients to this modality is vital to improve the therapeutic index. Thus far, we know that certain features of the primary tumor (ulcerated primaries and/or microscopic nodeYpositive disease) may predict the benefit of lower dosage regimens and the development of auto-immune manifestations during therapy are associated with therapeutic response. The former is being prospectively validated in an EORTC trial (18081).
Despite the high incidence of grade 3/4 adverse events observed in the phase III trials of ipilimumab in patients with metastatic melanoma, the presence of durable complete responses and significant improvements in RFS and OS have prompted adjuvant studies by EORTC and the U.S. intergroup.
Here, as with IFN->, biomarkers of response and treatment effect are needed. In the metastatic setting at least, elevated TILs, Treg, and IDO levels in pretreatment biopsies have been suggested to predict response to ipilimumab. Two separate groups of investigators have confirmed that ipilimumab therapy results in greater frequencies of circulating Tregs and increased expression of proliferation and polarization markers in CD4+ and CD8+ T cells, which may serve as indicators of the pharmacodynamic effects of ipilimumab. 74 The roles of CRP and of MDSC have been supported as biomarkers of CTLA-4 in the treatment of adjuvant disease and require evaluation in the adjuvant setting. 75, 76 A different paradigm may been seen in the molecularly targeted therapy for melanoma with BRAF, and MEK inhibitors, where high response rates and PFS and OS benefits have been observed in metastatic melanoma prompting consideration in the adjuvant setting. This is especially interesting because BRAF inhibition results in increased immune recognition and may abrogate tumor-mediated immune tolerance, allowing for rational combinations with a variety of immunotherapeutics. However, limiting adverse events such as rash, arthralgias, and cutaneous squamous cell carcinomas, the rapid development of BRAF resistance within months of initiating treatment, and the lack of data to demonstrate the kinetics of the immune alterations thus far pose obstacles to this approach. The use of neoadjuvant study designs in which patients would have tumor tissue biopsy before and after a limited exposure to BRAF therapy will be crucial to understand the potential range of effects that this agent may have, of relevance to the adjuvant therapeutic arena. These trial designs are now being developed and may draw from the experience with imatinib in gastrointestinal stromal tumor. 77, 78 Multiple scientific advances have been exploited in the clinic with dramatic results. However, the rational basis combinations and sequence of these agents to achieve significant and durable benefits in OS and RFS remain a focus of intense investigation. For now, the management of patients with high-risk melanoma remains high-dose IFN-> or enrollment into a clinical trial.
